• Home
  • NEW DAY MEDICINE
  • 2 (52) 2023
  • 30 -2 (52) 2023 — Musaeva D.M. — CYP2C19 GENE METABOLIZERS AS THE BASIS FOR PERSONALIZATION OF PHARMACOTHERAPY FOR ACID-DEPENDENT DISEASES

30 -2 (52) 2023 — Musaeva D.M. — CYP2C19 GENE METABOLIZERS AS THE BASIS FOR PERSONALIZATION OF PHARMACOTHERAPY FOR ACID-DEPENDENT DISEASES

CYP2C19 GENE METABOLIZERS AS THE BASIS FOR PERSONALIZATION OF PHARMACOTHERAPY FOR ACID-DEPENDENT DISEASES

Musaeva D.M. Bukhara State Medical Institute

Resume

The article deals with the issue of genotyping patients according to the genes of the pharmacokinetics of drugs MDR-1 and CYP2C19 in patients with acid-dependent diseases and, based on the data obtained, determine the type of the patient’s metabolizer present, which reveals the possibility of understanding the metabolic processes of drugs used to treat acid-related diseases. Also, the results of a study of the genotypes of the virulent Ice A gene of the bacterium H. pylori and their relationship with the genotypes of pharmacokinetic genes in combination in one organism are presented, the knowledge of which creates the possibility of personifying the pharmacotherapy of acid-dependent diseases.

Keywords: acid-dependent diseases, MDR-1 gene, CYP2C19 gene, types of metabolizers, virulent H. pylori Ice A gene, personification of pharmacotherapy

First page

172

Last page

178

For citation: Musaeva D.M. – CYP2C19 GENE METABOLIZERS AS THE BASIS FOR PERSONALIZATION OF PHARMACOTHERAPY FOR ACID-DEPENDENT DISEASES //New Day in Medicine 2(52)2023 172-178 https://clck.ru/33bAnh

LIST OF REFERENCES:

  1. Бакулина НВ, Маев ИВ, Савилова ИВ, Бакулин ИГ, Ильчишина ТА, Загородникова КА. и др. Эффективность эрадикации Helicobacter pyloriв зависимости от генетического полиморфизма CYP2C19, MDR1 и IL-1β. Терапевтический архив. 2019;(8):34–40. https://doi.org/10.26442/004036 60.2019.08.000380
  2. Исаева ГШ, Валиева РИ. Биологические свойства и вирулентность Helicobacter pylori // КМАХ. 2018. №1. URL: https://cyberleninka.ru/article/n/biologicheskie-svoystva-i-virulentnost-helicobacter-pylori
  3. Карева ЕН. Фармакогенетическое управление эффективностью и безопасностью ингибиторов протонных помп //РМЖ. – 2021. – Т. 29. – №. 4. – С. 68-73.
  4. Кличова ФК, Мавлянов ИР, Мусаева ДМ, Влияние генов на фармакотерапию язвенной болезни //Новый день в медицине 2020;2(30):142-145 https://newdaymedicine.com/index.php/2020/07/07/34-2-30-2020
  5. Леонова МВ. Генетический полиморфизм CYP2C19-предиктор клинической эффективности ингибиторов протонной помпы //Лечебное дело. – 2015. – №. 4. – С. 30-39.
  6. Максимов МЛ. и др. Клиническая фармакология и рациональная фармакотерапия для практикующих врачей. – 2021
  7. Мусаева ДМ, Сагдуллаева ГУ. Helicobacter pylori и его значение в возникновении и течении заболеваний гастродуоденальной зоны //Integrative dentistry and maxillofacial surgery. – 2022;1(2):69-74.
  8. Очилов АК, Очилова ГС. Клиническая значимость полиморфизмов гена CYP2C19 //Университетская наука: взгляд в будущее. – 2020;376-379.
  9. Цуканов В.В., Васютин А.В., Тонких Ю.Л., Смольникова М.В., Черепнин М.А., Масленникова Н.А., Павлова Н.В. Влияние полиморфизма CYP2C19 на эффективность лечения кислотозависимых заболеваний. Медицинский совет. 2022;16(14):81–87. https://doi.org/10.21518/2079-701X-2022-16-14-81-87.
  10. Brendan Dolan, Lucy Burkitt-Gray, Stephen Shovelin, Billy Bourke, Brendan Drumm, Marion Rowland, Marguerite Clyne,The use of stool specimens reveals Helicobacter pylori strain diversity in a cohort of adolescents and their family members in a developed country, International Journal of Medical Microbiology, 2018;308(2):247-255, ISSN 1438-4221, https://doi.org/10.1016/j.ijmm.2017.11.005.(https://www.sciencedirect.com/science/article/pii/S1438422117304101)
  11. Harris DM, Stancampiano FF, Burton MC, Moyer AM, Schuh MJ, Valery JR, Bi Y. Use of Pharmacogenomics to Guide Proton Pump Inhibitor Therapy in Clinical Practice. Dig Dis Sci. 2021;66(12):4120–4127. https://doi.org/10.1007/s10620-020-06814-1
  12. Kamilovich OA. Features of the Relationship of the Carrier of Allelic-Genotype Variants of the Cyp2c19 Gene in Patients With Chronic Gastritis //Journal of Innovation, Creativity and Art. – 2022; (1):20-26.
  13. Lanas A, Chan FK.L. Peptic ulcer disease //The Lancet. – 2017;390(10094):613-624.
  14. Lima JJ, Thomas CD, Barbarino J, Desta Z, Van Driest SL, El Rouby N. et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther. 2021;109(6):1417–1423. https://doi.org/10.1002/cpt.2015.
  15. Mamishi S, Eshaghi H, Mahmoudi S, Bahador A, Hosseinpour Sadeghi R, Najafi M, Farahmand F, Khodadad A, Pourakbari B. Intrafamilial transmission of Helicobacter pylori: genotyping of faecal samples. Br J Biomed Sci. 2016;73(1):38-43. doi:10.1080/09674845.2016.1150666. PMID: 27182676.
  16. Morino Y, Sugimoto M, Nagata N, Niikiura R, Iwata E, Hamada M. et al. Influence of Cytochrome P450 2C19 Genotype on Helicobacter pylori Proton Pump Inhibitor-Amoxicillin-Clarithromycin Eradication Therapy: A Meta-Analysis. Front Pharmacol. 2021;12:759249. https://doi.org/10.3389/ fphar.2021.759249
  17. Shah SC, Tepler A, Chung CP, Suarez G, Peek RM. Jr., Hung A. et al. Host Genetic Determinants Associated With Helicobacter pylori Eradication Treatment Failure: A Systematic Review and Meta-analysis. Gastroenterology 2021;161(5):1443–1459. https://doi.org/10.1053/j. gastro.2021.07.043.
  18. Wongphutorn P, Chomvarin C, Sripa B. et al. Detection and genotyping of Helicobacter pylori in saliva versus stool samples from asymptomatic individuals in Northeastern Thailand reveals intra-host tissue-specific H. pylori subtypes. BMC Microbiol  (2018); 18(10) https://doi.org/10.1186/s12866-018-1150-7

file

download